Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Symplekin scaffold protein (SYMPK) is a ubiquitously expressed, evolutionarily conserved nuclear protein functioning as a scaffold for the assembly of polyadenylation machinery during pre-mRNA processing and histone mRNA 3'-end maturation. Structurally, symplekin harbors a HEAT repeat domain supporting protein-protein interactions, and contributes to both the regulation of gene expression and the maintenance of mitotic spindle integrity. While it impacts cellular responses to certain drugs such as paclitaxel via modulation of mitosis, symplekin is not a direct drug target and is chiefly classified as a scaffold/structural protein rather than as a receptor, enzyme, transporter, or transcription factor. It is also found at tight junction plaques in select cell types, supporting possible roles in cell-cell adhesion and signaling.
None established for drugs, as symplekin is not a known pharmacological target. Paclitaxel sensitivity is indirectly modulated through symplekin’s role in mitosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Symplekin scaffold protein (SYMPK).